| 4.1 -0.66 (-13.87%) | 10-10 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.46 |
1-year : | 6.52 |
| Resists | First : | 4.67 |
Second : | 5.59 |
| Pivot price | 4.19  |
|||
| Supports | First : | 3.2 |
Second : | 2.66 |
| MAs | MA(5) : | 4.35 |
MA(20) : | 4.14 |
| MA(100) : | 3.9 |
MA(250) : | 12.11 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 60.4 |
D(3) : | 60.1 |
| RSI | RSI(14): 51.1 |
|||
| 52-week | High : | 56.25 | Low : | 0.68 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SHPH ] has closed above bottom band by 42.0%. Bollinger Bands are 14.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.96 - 4.98 | 4.98 - 5.01 |
| Low: | 4.45 - 4.47 | 4.47 - 4.49 |
| Close: | 4.72 - 4.75 | 4.75 - 4.79 |
Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers. The company was founded in 2012 and is based in Rockville, Maryland.
Fri, 10 Oct 2025
Shuttle Pharmaceuticals Signs LOI To Acquire AI Drug Discovery Firm Molecule.ai - Nasdaq
Fri, 10 Oct 2025
Shuttle Pharma signs letter of intent to acquire AI firm Molecule.ai - Investing.com
Fri, 10 Oct 2025
$10M LOI: Shuttle Pharmaceuticals to acquire Molecule.ai, adds Agentic AI and drug‑target modeling - Stock Titan
Thu, 09 Oct 2025
Shuttle Pharmaceuticals signs letter of intent to acquire Molecule.ai By Investing.com - Investing.com Nigeria
Thu, 09 Oct 2025
Shuttle to Enter $3.24 Billion AI Pharmaceutical Market - GlobeNewswire
Thu, 09 Oct 2025
$3.24B AI Pharma Market: Shuttle to Acquire Molecule.ai for $10M via LOI; Adds Agentic AI Mode - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 4.9 (%) |
| Held by Institutions | 5.6 (%) |
| Shares Short | 16 (K) |
| Shares Short P.Month | 17 (K) |
| EPS | -46.35 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.36 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -175.7 % |
| Return on Equity (ttm) | -551.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -10.93 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -11 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -0.09 |
| PEG Ratio | 0 |
| Price to Book value | 1.21 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.42 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|